Sign In
Last checked at 
18 Jan 2016 07:00
IXICO awarded four contracts worth a combined value of over £3.0m
Further cements IXICO's partnerships with leading pharmaceutical and biotechnology companies developing drugs for Alzheimer's disease.
18 January 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has recently been awarded four new contracts with leading pharmaceutical companies and a specialist biotechnology company, with a combined value of over £3.0m.
The contracts are for global clinical trials of novel drugs for Alzheimer's disease which span the three major phases of drug development and are expected to run for the next two to four years, subject to the drugs successfully progressing through the clinical trials process. They will utilise IXICO's expertise in the Alzheimer's field and our proprietary TrialTracker® and Assessa® digital platforms to collect imaging data and quantify changes in disease pathology in subjects enrolled in the study.
The award of these contracts builds on IXICO's expertise in brain health following a long term contract for a Phase II/III global study in neurodegenerative disease and selection as the imaging analysis partner within The European Prevention of Alzheimer's Dementia Initiative (EPAD), announced in 2015.
Professor Derek Hill, Chief Executive Officer of IXICO, commented: "We are very pleased to have been awarded these significant projects. Not only do they validate the value our digital platforms provide, but also highlight the strength of IXICO's relationships with pharmaceutical and biotechnology companies developing drugs for Alzheimer's disease. The revenues from these contracts augment the board's confidence in meeting market expectations."
Enquiries:
IXICO plc | +44 20 3763 7499 |
Derek Hill, CEO | |
Susan Lowther, CFO | |
Charles Spicer, VP Corporate Development | |
Peel Hunt LLP (Nominated Adviser and Broker) | +44 20 7418 8900 |
James Steel / Oliver Jackson | |
Daniel Stewart & Company (Joint Broker) | +44 207 776 6550 |
Martin Lampshire / David Coffman | |
FTI Consulting Limited (Investor Relations) | +44 20 3727 1000 |
Simon Conway / Mo Noonan / Matthew Moss |
Notes to Editors
About IXICO
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.
More information is available on www.ixico.com.
About Assessa®
IXICO's digital platform technology which can extract biomarkers from imaging data and combine these biomarkers with demographic, cognitive and functional information to improve the precision of patient stratification, differential diagnosis and predict likely disease progression of dementia and other neurodegenerative diseases. Available in both research and medical device forms, Assessa® can support both stratification of patients in clinical trials and diagnosis of brain diseases in the clinic.
More information about Assessa is available on www.ixico.com/products/assessa
Follow the stocks
